Publication year
2017Source
Eurointervention, 12, 14, (2017), pp. 1689-1696ISSN
Publication type
Article / Letter to editor

Display more detailsDisplay less details
Organization
Cardiology
Journal title
Eurointervention
Volume
vol. 12
Issue
iss. 14
Page start
p. 1689
Page end
p. 1696
Subject
Radboudumc 16: Vascular damage RIHS: Radboud Institute for Health SciencesAbstract
AIMS: Our aim was to test the feasibility and safety of the transfemoral PulseCath iVAC 2L (PulseCath, Amsterdam, The Netherlands). METHODS AND RESULTS: Circulatory support devices are helpful adjunctive tools to perform high-risk percutaneous coronary interventions (PCI). The PulseCath iVAC 2L is a novel pulsatile circulatory support system capable of generating output of up to 2 L/min. We performed a prospective clinical pilot study enrolling 14 patients who underwent high-risk PCI under protection with the iVAC 2L. Median age was 74 (56-84) years. Implantation of the iVAC 2L was successful in 13 (93%) patients. Median device flow was 1.4 (1.1-2.0) L/min. Total support time was 67 (23-149) minutes. The use of iVAC 2L support was associated with a better mean arterial pressure and cardiac output during the procedure. Angiographic success was 100%. There was one major procedural complication related to the 19 Fr access sheath. There were no major adverse events at three-month follow-up. CONCLUSIONS: Circulatory support with the iVAC 2L device is feasible and safe in patients undergoing high-risk PCI.
This item appears in the following Collection(s)
- Academic publications [229074]
- Faculty of Medical Sciences [87745]
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.